We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Cocrystal Pharma Inc (COCP) USD0.01

Sell:$0.74 Buy:$0.75 Change: $0.0511 (7.30%)
Market closed |  Prices as at close on 7 December 2021 | Switch to live prices |
Change: $0.0511 (7.30%)
Market closed |  Prices as at close on 7 December 2021 | Switch to live prices |
Change: $0.0511 (7.30%)
Market closed |  Prices as at close on 7 December 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Cocrystal Pharma, Inc. is a biotechnology company. The Company focuses on developing antiviral therapeutics that inhibit the essential viral replication function of RNA viruses causing acute and chronic viral diseases. The Company focuses on treating influenza virus, coronavirus, and norovirus infections by discovering and developing drug candidates targeting the viral replication process. The Company uses computational methods to screen and design product candidates using cocrystal structural information. The Company’s Hepatitis C Virus (HCV) Non-Nucleoside Polymerase Inhibitor CC-31244 is a pan-genotypic inhibitor of NS5B polymerase for the treatment of hepatitis C infection. The Company’s CC-42344 is a PB2 inhibitor for the treatment of influenza A infection. It has also developed chemical libraries consisting of non-nucleoside inhibitors, metal-binding inhibitors, and drug-like fragments.

Contact details

19805 N Creek Pkwy
United States
+1 (786) 4591831

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$68.23 million
Shares in issue:
97.47 million
United States
US dollar

Key personnel

  • Sam Lee
    President, Interim Co-Chief Executive Officer
  • James Martin
    Co-Chief Executive Officer, Chief Financial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.